Immune Thrombocytopenia historical perspective: Difference between revisions

	Immune Thrombocytopenia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Immune Thrombocytopenia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Immune Thrombocytopenia historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Immune Thrombocytopenia historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Immune Thrombocytopenia historical perspective
CDC on Immune Thrombocytopenia historical perspective
Immune Thrombocytopenia historical perspective in the news
Blogs on Immune Thrombocytopenia historical perspective
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Immune Thrombocytopenia historical perspective

Revision as of 04:52, 20 January 2021

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]

There is limited information about the historical perspective of [disease name].

OR

Idiopathic Thrombocytopenia was first described by a German poet Paul Werlhof, in 1735. He referred to classical signs of ITP as mucosal bleeding, black and purple spots on the patient's arm, due to this description, ITP is called Werlhof's disease.

The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
In 1881, an Italian pathologist, Guilio Bizzozero was the first to discover the role of platelet in hemostasis.
In 1889, George Hayem proved the association between purpura and the development of thrombocytopenia by physically counting the patient's platelet.
In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

@@ Line 16: / Line 16: @@
 *The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
-*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
+*In 1881, an Italian pathologist, Guilio Bizzozero was the first to discover the role of platelet in hemostasis.
+*In 1889, George Hayem proved the association between purpura and the development of thrombocytopenia by physically counting the patient's platelet.
 *In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].